CORT — Corcept Therapeutics Share Price
0.000.00%
Last trade - 00:00- $6.57bn
- $6.18bn
- $675.04m
- 92
- 14
- 63
- 57
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 28.48 | ||
| PEG Ratio (f) | 0.77 | ||
| EPS Growth (f) | 58.48% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 9.66 | ||
| Price to Tang. Book | 9.66 | ||
| Price to Free Cashflow | 33.52 | ||
| Price to Sales | 9.73 | ||
| EV to EBITDA | 44.7 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 19.57% | ||
| Return on Equity | 23.81% | ||
| Operating Margin | 20.29% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 353.87 | 365.98 | 401.86 | 482.38 | 675.04 | 905.38 | 1,195.51 | 17.11% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +11.09 | +4.64 | -2.09 | +8.61 | +31 | +36.22 | +96.87 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Corcept Therapeutics Incorporated is a commercial-stage company. The Company is engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.
Directors
- James Wilson NEC (77)
- Joseph Belanoff PRE (63)
- Atabak Mokari CFO (44)
- Joseph Lyon CAO (43)
- Hazel Hunt CSO (61)
- William Guyer OTH
- Sean Maduck OTH (44)
- Gary Robb SEC (58)
- Joshua Murray DRC
- Gregg Alton IND (55)
- George Baker IND (78)
- Gillian Cannon IND (57)
- David Mahoney IND (66)
- Kimberly Park IND (57)
- Daniel Swisher IND (58)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 13th, 1998
- Public Since
- April 15th, 2004
- No. of Shareholders
- 522
- No. of Employees
- 500
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 105,503,432
- Address
- 101 REDWOOD SHORES PARKWAY, REDWOOD CITY, 94065
- Web
- https://www.corcept.com/
- Phone
- +1 6506888803
- Auditors
- Ernst & Young LLP
Upcoming Events for CORT
Corcept Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Corcept Therapeutics Inc Earnings Release
Similar to CORT
60 Degrees Pharmaceuticals
NASDAQ Capital Market
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
FAQ
What is the Corcept Therapeutics share price?
As of Today at 20:04 UTC, shares in Corcept Therapeutics are trading at $62.24. This share price information is delayed by 15 minutes.
How has the Corcept Therapeutics share price performed this year?
Shares in Corcept Therapeutics last closed at $62.24 and the price had moved by +170.61% over the past 365 days. In terms of relative price strength the Corcept Therapeutics share price has outperformed the S&P500 Index by +154.45% over the past year.
What are the analyst and broker recommendations for Corcept Therapeutics?
The overall consensus recommendation for Corcept Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Corcept Therapeutics dividend yield?
Corcept Therapeutics does not currently pay a dividend.
Does Corcept Therapeutics pay a dividend?
Corcept Therapeutics does not currently pay a dividend.
When does Corcept Therapeutics next pay dividends?
Corcept Therapeutics does not currently pay a dividend.
How do I buy Corcept Therapeutics shares?
To buy shares in Corcept Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Corcept Therapeutics?
As of the previous close price of $62.24, shares in Corcept Therapeutics had a market capitalisation of $6.57bn.
Where are Corcept Therapeutics shares listed?
Here are the trading details for Corcept Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CORT
What kind of share is Corcept Therapeutics?
Based on an overall assessment of its quality, value and momentum Corcept Therapeutics is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Corcept Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Corcept Therapeutics is $143.25. That is 130.16% above the last closing price of $62.24.
Analysts covering Corcept Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of $1.70 for the next financial year.
Find out moreWhat is the trend in the Corcept Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Corcept Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +38.63%.
As of the last closing price of $62.24, shares in Corcept Therapeutics were trading +22.1% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Corcept Therapeutics PE Ratio?
The Corcept Therapeutics PE ratio based on its reported earnings over the past 12 months is 28.48. The shares last closed at $62.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Corcept Therapeutics?
Corcept Therapeutics' management team is headed by:
- James Wilson - NEC
- Joseph Belanoff - PRE
- Atabak Mokari - CFO
- Joseph Lyon - CAO
- Hazel Hunt - CSO
- William Guyer - OTH
- Sean Maduck - OTH
- Gary Robb - SEC
- Joshua Murray - DRC
- Gregg Alton - IND
- George Baker - IND
- Gillian Cannon - IND
- David Mahoney - IND
- Kimberly Park - IND
- Daniel Swisher - IND